Medicine and Dentistry
Circulating Tumor DNA
100%
Nodular Melanoma
89%
Neoplasm
75%
Circulating Tumor Cell
52%
Ovarian Cancer
38%
Biological Marker
37%
Metastatic Melanoma
36%
Adverse Event
33%
Nivolumab
32%
Chemotherapy
32%
Follow up
30%
Diseases
30%
Recurrent Disease
29%
Droplet Digital Polymerase Chain Reaction
28%
Progression Free Survival
26%
Solid Malignant Neoplasm
25%
Toxicity
22%
Tislelizumab
22%
Overall Survival
20%
Immunotherapy
20%
Platinum
19%
Promoter Region
18%
Programmed Death 1 Ligand 1
18%
Programmed Cell Death
17%
Antineoplastic Activity
17%
MEK Inhibitor
17%
Programmed Death-Ligand 1
17%
Ipilimumab
17%
Krukenberg Tumor
16%
Pharmacokinetics
16%
Pembrolizumab
15%
Non Small Cell Lung Cancer
15%
Ligand
14%
Mesothelioma
12%
Prognosis
12%
Immune System
11%
Monoclonal Antibody
11%
Bevacizumab
11%
High Risk Population
11%
Afuresertib
11%
Physical Activity
11%
Endometrial Cancer
11%
Cervical Cancer
11%
Camrelizumab
11%
RNA
11%
Pamiparib
11%
Fibulin
11%
Exercise
11%
Human Leukocyte Antigen
11%
Woman
11%
Agricultural and Biological Sciences
DNA
81%
Biomarkers
66%
T Cell
55%
Mutation
50%
PD-L1
46%
Clinical Trials
33%
Transponder
26%
Toxicity
23%
Meta-Analysis
23%
Pharmacokinetics
20%
Pembrolizumab
20%
Cell Death
19%
Monoclonal Antibody
17%
Ipilimumab
17%
Flow Cytometry
17%
Regulatory T Cell
16%
Confidence Interval
15%
Immune System
15%
Odds Ratio
13%
Systematic Review
13%
Cell Lines
13%
Poly ADP Ribose Polymerase
13%
Endpoints
12%
Bevacizumab
11%
Proteins
11%
Paclitaxel
11%
Risk Groups
11%
Agonist
11%
Antigens
11%
CA-125
11%
Epidermal Growth Factor Receptor
11%
Programmed Cell Death 1
11%
Immune Response
11%
Physical Activity
11%
Cyclophosphamide
11%
Mesothelin
11%
Immunocytochemistry
11%
RNA
11%
Receptors
9%
Dendritic Cell
9%
Quality of Life
9%
Glucocorticoid
8%
Tumor Necrosis Factor Receptor
8%
Weight Loss
8%
Antibodies
7%
Australians
7%
CTLA-4
7%
Tyrosine
7%
Enzymes
5%
Nucleic Acids
5%
Pharmacology, Toxicology and Pharmaceutical Science
Circulating Tumor DNA
41%
Melanoma
37%
Chemotherapy
37%
Nivolumab
24%
Adverse Event
24%
Tislelizumab
22%
Solid Malignant Neoplasm
22%
Toxicity
20%
Progression Free Survival
20%
Metastatic Melanoma
20%
Mitogen Activated Protein Kinase Kinase Inhibitor
17%
Neoplasm
16%
Pharmacokinetics
16%
Immune Checkpoint Inhibitor
14%
Platinum
13%
Recurrent Disease
13%
Ipilimumab
13%
Tolerability
12%
Pembrolizumab
11%
Monoclonal Antibody
11%
Bevacizumab
11%
Programmed Death-Ligand 1
11%
Carboplatin
11%
Diseases
11%
Immunotherapy
11%
Programmed Death 1 Ligand 1
9%
Paclitaxel
7%
Vaccine
7%
Overall Survival
7%
Disease Exacerbation
7%
Minimal Residual Disease
7%
Ovary Carcinoma
6%
Cyclophosphamide
6%
Maximum Tolerated Dose
6%
Immunoglobulin G4
5%
Biological Marker
5%
Phosphotransferase Inhibitor
5%
Monotherapy
5%
Diarrhea
5%